All In Biotech

Drug Trial Radar · NCT07286266

A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

450

Planned (sponsor's estimate)

Start

Jun 18, 2026

Primary completion

Jul 22, 2030

Study completion Jul 22, 2030

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
GOG, ENGOT, APGOT
First posted
Dec 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating ovarian cancer compared to standard treatments. The study also assesses whether Mo-Rez is safe and tolerated well by participants compared to standard treatments and aims to provide a better understanding of the main side effects of the drug.

Conditions

  • Ovarian Neoplasms

Interventions

  • Mocertatug rezetecanDrug

    Mocertatug rezetecan will be administered

  • PaclitaxelDrug

    Paclitaxel will be administered

  • Pegylated liposomal doxorubicin (PLD)Drug

    PLD will be administered

  • TopotecanDrug

    Topotecan will be administered

  • GemcitabineDrug

    Gemcitabine will be administered

  • PembrolizumabDrug

    Pembrolizumab will be administered

  • BevacizumabDrug

    Bevacizumab will be administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) by BICRTime frame: Up to approximately 212 weeks
  2. Overall Survival (OS)Time frame: Up to approximately 212 weeks

Locations

22 sites in 5 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Randwick, New South Wales, Australia · Recruiting

  • GSK Investigational Site

    Auchenflower, Queensland, Australia · Recruiting

  • GSK Investigational Site

    Toronto, Ontario, Canada · Recruiting

  • GSK Investigational Site

    Montreal, Quebec, Canada · Recruiting

  • GSK Investigational Site

    Montreal, Quebec, Canada · Recruiting

  • GSK Investigational Site

    Fukuoka, Japan · Recruiting

  • GSK Investigational Site

    Fukuoka, Japan · Recruiting

  • GSK Investigational Site

    Hokkaido, Japan · Recruiting

  • GSK Investigational Site

    Hyōgo, Japan · Recruiting

  • GSK Investigational Site

    Kanagawa, Japan · Recruiting

  • GSK Investigational Site

    Kanagawa, Japan · Recruiting

  • GSK Investigational Site

    Mie, Japan · Recruiting

  • GSK Investigational Site

    Okinawa, Japan · Recruiting

  • GSK Investigational Site

    Osaka, Japan · Recruiting

  • GSK Investigational Site

    Saitama, Japan · Recruiting

  • GSK Investigational Site

    Tottori, Japan · Recruiting

  • GSK Investigational Site

    Gyeonggi-do, South Korea · Recruiting

  • GSK Investigational Site

    Seoul, South Korea · Recruiting

  • GSK Investigational Site

    Seoul, South Korea · Recruiting

  • GSK Investigational Site

    Suwon Kyunggi-do, South Korea · Recruiting

  • GSK Investigational Site

    Seoul, Seoul Teugbyeolsi, South Korea · Recruiting

  • GSK Investigational Site

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.